July brought a broad range of regulatory developments across Europe, the UK and the United States, with progress across dermatology, respiratory disease, neurology, oncology and rare conditions.

AbbVie’s Rinvoq became the first and only systemic medication approved in the EU for non-segmental vitiligo, while the EMA’s CHMP recommended Nezglyal for boys aged 2–12 with cerebral adrenoleukodystrophy, a rare neurodegenerative disease with no approved pharmacological treatments in the EU. AstraZeneca’s Trixeo Aerosphere also received a positive CHMP recommendation for asthma in patients aged 12 and over.

Almirall’s application to extend Ebglyss to children and adolescents with moderate-to-severe atopic dermatitis was accepted by the EMA, while Teva submitted an FDA application for ecopipam, which could become the first new FDA-approved treatment for paediatric Tourette syndrome in more than a decade.

In the UK, Boehringer Ingelheim’s Jascayd received MHRA marketing authorisation for idiopathic and progressive pulmonary fibrosis, representing the first treatment breakthrough in pulmonary fibrosis in over a decade. Bristol Myers Squibb’s New Drug Application for mezigdomide was also accepted by the FDA for relapsed or refractory multiple myeloma.

Further regulatory activity included FDA Priority Review for Pfizer’s Talzenna plus Xtandi in metastatic castration-sensitive prostate cancer, supported by phase 3 data showing a 52% reduction in the risk of radiographic progression or death.

Alongside product developments, the EMA’s Pharmacovigilance Risk Assessment Committee reviewed newly detected safety signals involving medicines including atogepant, CGRP-targeting migraine therapies, oseltamivir, zanamivir, sacituzumab govitecan, selpercatinib and sevoflurane, reinforcing the continued importance of pharmacovigilance and post-marketing safety monitoring.

Advances in research and innovative therapies

Research activity continued to produce encouraging results across dermatology, rare disease, neuroscience and women’s health, while highlighting the growing importance of patient-centred clinical development.

Pfizer reported positive phase 3 results for Litfulo in non-segmental vitiligo, with significant improvements in facial and total-body repigmentation. Takeda also announced positive phase 3 data for zasocitinib in moderate-to-severe plaque psoriasis and plans regulatory submissions while continuing development across other immune-mediated conditions.

Sanofi reported positive phase 3 Baby-COMET results for Nexviazyme in infantile-onset Pompe disease, while Biogen and Eisai reported real-world Leqembi data showing that 82.5% of early Alzheimer’s patients remained stable or improved after an average of 17 months of treatment.

Veradermics also reported positive phase 2 data for VDPHL01 in female pattern hair loss, while a biomarker-based approach to spontaneous preterm birth demonstrated the potential of more personalised, risk-based care to improve maternal and neonatal outcomes.

Beyond clinical results, several articles explored how patient involvement and study design are evolving. Topics included meaningful patient participation in EU Health Technology Assessment, translating patient stories into practical support, improving informed consent through clearer communication, and designing digital clinical trials that are more accessible to older participants.

Industry partnerships, investments and acquisitions

Strategic acquisitions remained a major feature of the life sciences sector as organisations strengthened portfolios across neuroscience, oncology, rare disease and endocrine medicine.

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion, adding rapid-acting neuroplastogen therapies for treatment-resistant depression and other mental health conditions. Novartis announced a deal worth up to $1.5 billion for Myricx Bio, gaining novel antibody-drug conjugate technology for solid tumours.

Vertex agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, expanding into endocrine diseases, while Ipsen announced an acquisition of Memo Therapeutics worth more than €700 million to strengthen its rare disease pipeline. Zymeworks also agreed to acquire Theravance Biopharma for approximately $929 million.

Klick Health acquired Oxford PharmaGenesis to expand its scientific, medical and market access capabilities, while AstraZeneca entered a $1.5 billion licence agreement with Dizal Pharmaceutical for global rights to the lung cancer treatment Zegfrovy.

Healthcare initiatives and patient-centred innovation

Healthcare discussions in July continued to focus on patient experience, inclusion, women’s health and the changing competitive environment for life sciences.

Thought leadership highlighted the need to move beyond narrow approaches to women’s healthcare and redesign care around female biology, experiences and clinical needs. Alzheimer’s organisations also called for women’s brain health to become a greater global priority, noting that women account for nearly two-thirds of Alzheimer’s diagnoses.

The newsletter also examined the UK’s position in an increasingly competitive global life sciences market, highlighting the growing importance of speed to revenue, pricing flexibility, investment and adapting to the priorities of global pharmaceutical companies.

Market access, patient engagement and healthcare communications

Patient engagement, commercial strategy and healthcare communication remained prominent themes throughout July.

Articles explored how creativity can help pharmaceutical campaigns cut through complexity while remaining grounded in disease understanding, patient behaviour and unmet needs. Inizio Engage also launched Connected Insights, combining Medical Information interactions, AI-enabled tools and global infrastructure to support Medical Affairs strategy across more than 20 languages.

Launch excellence was another major theme, with emphasis on early cross-functional collaboration across clinical, regulatory, commercial and market access teams, HTA-ready evidence generation, and stronger alignment between endpoints, payer expectations and patient needs. Rare disease launches were also highlighted as requiring earlier and more effective Medical–Commercial alignment.

Looking ahead

July’s developments reflect a life sciences industry continuing to balance scientific innovation with stronger patient involvement, evidence generation, accessibility and commercial execution.

From important regulatory milestones and encouraging late-stage research to major acquisitions, evolving healthcare priorities and more patient-centred approaches to communication and clinical trials, organisations continue to invest across the full healthcare ecosystem.

As regulatory, clinical and commercial environments become increasingly complex, future success will depend on combining innovative science with clear communication, integrated evidence strategies and a deeper understanding of patient and healthcare system needs.

Essjay Solutions will continue to monitor these developments and provide insights into the latest regulatory, clinical, research, healthcare and market access trends.